Lercaril

Enalapril maleate / lercanidipine hydrochloride, the active ingredient in Lercaril, is an ACE inhibitor/calcium channel blocker combination presented as a tablet for oral use. It treats essential hypertension in adult patients.

GNH USA supplies Lercaril as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercaril is an antihypertensive medication that acts on the renin‑angiotensin system and vascular smooth‑muscle calcium channels. - Essential hypertension: provides additive blood‑pressure reduction when monotherapy is insufficient. - Hypertension requiring dual therapy: offers simultaneous ACE inhibition and calcium‑channel blockade in a single tablet. - Uncontrolled blood pressure on single agents: improves control by targeting two complementary pathways.

Lercaril may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Cough: dry, persistent throat irritation. - Dizziness or light‑headedness, especially after standing. - Headache: mild to moderate intensity. - Peripheral edema: swelling of ankles or feet. - Flushing: transient warmth and redness of the skin. - Fatigue: generalized tiredness.

Serious or Rare Side Effects: - Angioedema: rapid swelling of face, lips, tongue, or airway. - Severe hypotension: marked drop in blood pressure causing fainting. - Hepatic dysfunction: abnormal liver enzymes or jaundice. - Neutropenia or leukopenia: reduced white‑blood‑cell counts. - Myocardial infarction: rare occurrence of heart attack. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before prescribing Lercaril, clinicians should evaluate patient‑specific risk factors and monitor therapy. - Renal function: assess creatinine clearance and adjust if impaired. - Electrolytes: monitor potassium and sodium levels regularly. - History of angioedema: avoid use in patients with prior episodes. - Pregnancy: contraindicated due to ACE‑inhibitor teratogenicity; discontinue if pregnancy is detected. - Elderly patients: start at lower dose and monitor for hypotension. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lercaril can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Aliskiren: combined use may cause excessive hypotension and renal impairment. - Potassium‑sparing diuretics or supplements: increase risk of hyperkalaemia. - Lithium: may raise lithium concentrations, leading to toxicity. - Dual ACE‑inhibitor/ARB therapy: heightened risk of renal dysfunction and hyperkalaemia. - NSAIDs (high‑dose): can blunt antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may enhance antihypertensive effect, watch for volume depletion. - CYP3A4 inhibitors (e.g., erythromycin, clarithromycin): can increase lercanidipine levels. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce lercanidipine exposure. - Other antihypertensives: additive blood‑pressure lowering, monitor for hypotension. - Grapefruit juice: may raise lercanidipine concentrations, advise avoidance.